v3.26.1
Net Loss Per Share
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Net Loss Per Share

13. Net Loss Per Share

The following table sets forth the reconciliation of basic and diluted loss per share for the three and six months ended June 30, 2026 and 2025 (in thousands except per share data):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Net loss

 

$

(114,986

)

 

$

(44,048

)

 

$

(160,636

)

 

$

(70,128

)

Less: Net loss attributable to noncontrolling interest

 

 

(1,486

)

 

 

(1,740

)

 

 

(3,866

)

 

 

(1,740

)

Deemed dividend for Vivasor preferred shares repurchase

 

 

(1,229

)

 

$

 

 

 

(1,229

)

 

 

 

Deemed dividend for anti-dilution adjustments to Oramed Penny Warrants upon reverse stock-split

 

 

 

 

$

(43,753

)

 

 

 

 

 

(43,753

)

Net loss for basic and diluted loss per share available to common stockholders

 

$

(114,729

)

 

$

(86,061

)

 

$

(157,999

)

 

$

(112,141

)

Weighted average number of shares outstanding

 

 

6,892

 

 

 

5,095

 

 

 

6,891

 

 

 

5,080

 

Weighted average Common Stock warrants exercisable for nominal consideration

 

 

 

 

 

6,500

 

 

 

 

 

 

6,500

 

Weighted average number of shares, basic and diluted

 

 

6,892

 

 

 

11,595

 

 

 

6,891

 

 

 

11,580

 

Loss per share

 

 

 

 

 

 

 

 

 

 

 

 

Basic & diluted

 

$

(16.65

)

 

$

(7.42

)

 

$

(22.93

)

 

$

(9.68

)

 

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Premium paid on redemption of Series A Preferred Stock was added to the net loss to arrive at loss available for common stockholders as it represents a dividend to the Series A preferred stockholder. Diluted earnings per share is computed using the weighted average number of shares of Common Stock and, if dilutive, potential shares of Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable).

 

In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. Shares of the Semnur Dividend Shares, as declared by the Board on October 27, 2024, and not yet distributed as of June 30, 2026 and 2025, are also excluded from the computation of net loss per share because the associated Series 1 Preferred Stock is not considered to be a participating security. On February 2, 2026, the Board approved revocation of the declaration of the Semnur Dividend Shares. No shares of Series 1 Mandatory Exchangeable Preferred Stock had ever been issued or outstanding as of February 2, 2026.

On February 3, 2026, in connection with the Dividend Revocation, the Company filed the Certificate of Elimination of Semnur Dividend Shares with the Secretary of State of the State of Delaware. The Certificate of Elimination, which became effective immediately upon filing, eliminated the previously designated 5,000,000 shares of Semnur Dividend Shares and caused such shares to resume their status as undesignated shares of preferred stock of the Company. No shares of Semnur Dividend Shares were issued or outstanding upon the filing of the Certificate of Elimination.

 

In accordance with FASB ASC 260, Earnings Per Share, Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September 21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock were not vested as of the closing date of September 21, 2023, and the vesting was based on the passage of time, the Company’s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein), therefore are included in the computation for basic and diluted net income per share once all other exercise contingencies were removed except for the passage of time.

 

The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:

 

 

 

June 30,

 

 

June 30,

 

 

 

2026

 

 

2025

 

Stock options

 

 

1,474,612

 

 

 

1,009,938

 

Retainer Shares

 

 

399,999

 

 

 

399,999

 

Public Warrants

 

 

156,115

 

 

 

156,220

 

Private Warrants

 

 

28,572

 

 

 

28,572

 

Shares issuable under the ESPP

 

 

1,645

 

 

 

21,713

 

Shares issuable under the SIPA

 

 

8,571

 

 

 

8,571

 

February 2024 BDO Firm Warrants

 

 

108,686

 

 

 

108,686

 

February 2024 BDO Representative Warrants

 

 

13,446

 

 

 

13,446

 

April 2024 RDO Common Warrants

 

 

 

 

 

428,572

 

April 2024 RDO Placement Agent Warrants

 

 

34,286

 

 

 

34,286

 

Deposit Warrants

 

 

3,250,000

 

 

 

3,250,000

 

October 2024 Noteholder Warrants

 

 

107,142

 

 

 

214,284

 

October 2024 Placement Agent Warrants

 

 

104,848

 

 

 

104,848

 

December 2024 RDO Common Warrants

 

 

537,294

 

 

 

1,642,871

 

StockBlock Warrants

 

 

131,470

 

 

 

131,472

 

Shares issuable under Tranche B Notes

 

 

327,555

 

 

 

914,822

 

Exchange Warrants

 

 

500,000

 

 

 

 

September 2025 Warrants

 

 

275,000

 

 

 

 

November 2025 Warrants

 

 

1,356,594

 

 

 

 

November 2025 Placement Agent Warrants

 

 

72,352

 

 

 

 

February 2026 Warrants

 

 

100,000

 

 

 

 

Total

 

 

8,988,187

 

 

 

8,468,300